Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55572 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5252 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5254 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16734 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16722 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-22 |
filingDate |
2006-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2014-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2014-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-101357204-B1 |
titleOfInvention |
Varicella zoster antivirus |
abstract |
The present invention relates to the use of an immunogenic composition comprising a VZV gE or an immunogenic fragment thereof and a TH-1 adjuvant in the manufacture of a medicament for preventing or reducing the attenuation of shingles and / or post-herpetic neuralgia. Also claimed is a composition comprising a truncated VZV gE antigen and an adjuvant containing QS21, cholesterol and 3D MPL. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021172971-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210046634-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190121956-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022010213-A1 |
priorityDate |
2005-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |